Category Archives: Kleiner Perkins

The Wing, a co-working space for women, opens its doors in San Francisco

Women-focused co-working space The Wing has made its way to California, opening its first of two planned locations in the state this morning. On Sansome Street in San Francisco’s Financial District, The Wing hopes to attract professional women able to shell out $215 per month for access to its 8,000-square-foot workspace, which is complete with conference rooms, a cafe, a library stocked with books on feminist theory, a lactation room and more. In addition to its chic decor and feminist messaging, The Wing is also known for its […]

Read more

Munich Re buys IoT middleware startup, relayr, in deal worth $300M

Berlin based Internet of Things (IoT) startup relayr, whose middleware platform is geared towards helping industrial companies unlock data insights from their existing machinery and production line kit by linking Internet connected sensors and edge devices to platform controls, has been acquired by insurance group Munich Re in a deal which values the company at $300 million. relayr was founded back in 2013 with the initial aim of helping software developers hack around with hardware, at a time when developer interest in IoT was just taking off. […]

Read more

Gusto raises $140 million to go after small business payroll and benefits with more gusto

Gusto, which sells payroll, benefits and human resources management and monitoring services to small businesses, has raised $140 million in its latest round of funding. The company said it will use the money to add new services to increase payment flexibility for employees. The company launched a new service called Flexible Pay, which gives employees a way to get paid no matter when a company’s pay schedule dictates. It seems sort of like a payday loan, where a percentage of the salary is taken by Gusto for […]

Read more

While tech waffles on going public, biotech IPOs boom

For people who make investment decisions based on revenues and projected earnings, biotech IPOs are kind of a non-starter. Not only are new market entrants universally unprofitable, most have zero revenue. Going public is mostly a means to raise money for clinical trials, with red ink expected for years to come. That pattern may be one reason the venture capital press, Crunchbase News included, tends to devote a disproportionately small portion of coverage to biotech IPOs. It’s more exciting to watch a big-name internet company pop in first-day trading or poke fun at […]

Read more